A pharmaceutical composition comprising a polynucleotide encoding a fusion protein for use in treating cervical tumor in a human subject in need thereof, wherein the subject is to be administered a first dose of the composition and is to be administered a second dose of the composition, wherein the subject exhibits an increased cellular immune response after administration of the first dose when measured, wherein the increased cellular immune response comprises an increased CD8 T cell response, increased CD4 T cell response, increased cytokine secretion, or any combination thereof; wherein the fusion protein comprises: an N-terminal portion of an E6 protein of HPV16 comprising the amino acid sequence of residues 1-85 of SEQ ID NO:2, an N-terminal portion of an E7 protein of HPV16 comprising the amino acid sequence of residues 1-65 of SEQ ID NO:6, a C-terminal portion of an E6 protein of HPV16 comprising the amino acid sequence of residues 71-158 of SEQ ID NO:2, a C-terminal portion of an E7 protein of HPV16 comprising the amino acid sequence of residues 51-98 of SEQ ID NO:6, an N-terminal portion of an E6 protein of HPV18 comprising the amino acid sequence of residues 1-85 of SEQ ID NO:4, an N-terminal portion of an E7 protein of HPV18 comprising the amino acid sequence of residues 1-65 of SEQ ID NO: 8, a C-terminal portion of an E6 protein of HPV18 comprising the amino acid sequence of residues 71-158 of SEQ ID NO:4, and a C-terminal portion of an E7 protein of HPV18 comprising the amino acid sequence of residues 51-105 of SEQ ID NO:8, wherein the fusion protein does not bind to p53 or does not form a dimer with an E6 protein of HPV16 or HPV 18 and wherein the fusion protein does not bind to pRb or does not form a dimer with an E7 protein of HPV16 or HPV18, and (a) wherein the first dose is at least about 1mg, at least about 1.5mg, at least about 2mg, at least about 2.5mg, at least about 3mg, at least about 3.5mg, at least about 4mg, at least about 4.5mg, or at least about 5mg; and/or (b) wherein the second dose is at least about 1mg, at least about 1.5mg, at least about 2mg, at least about 2.5mg, at least about 3mg, at least about 3.5mg, at least about 4mg, at least about 4.5mg, or at least about 5mg. an N-terminal portion of an E6 protein of HPV16 comprising the amino acid sequence of residues 1-85 of SEQ ID NO:2, an N-terminal portion of an E7 protein of HPV16 comprising the amino acid sequence of residues 1-65 of SEQ ID NO:6, a C-terminal portion of an E6 protein of HPV16 comprising the amino acid sequence of residues 71-158 of SEQ ID NO:2, a C-terminal portion of an E7 protein of HPV16 comprising the amino acid sequence of residues 51-98 of SEQ ID NO:6, an N-terminal portion of an E6 protein of HPV18 comprising the amino acid sequence of residues 1-85 of SEQ ID NO:4, an N-terminal portion of an E7 protein of HPV18 comprising the amino acid sequence of residues 1-65 of SEQ ID NO: 8, a C-terminal portion of an E6 protein of HPV18 comprising the amino acid sequence of residues 71-158 of SEQ ID NO:4, and a C-terminal portion of an E7 protein of HPV18 comprising the amino acid sequence of residues 51-105 of SEQ ID NO:8, (a) wherein the first dose is at least about 1mg, at least about 1.5mg, at least about 2mg, at least about 2.5mg, at least about 3mg, at least about 3.5mg, at least about 4mg, at least about 4.5mg, or at least about 5mg; and/or (b) wherein the second dose is at least about 1mg, at least about 1.5mg, at least about 2mg, at least about 2.5mg, at least about 3mg, at least about 3.5mg, at least about 4mg, at least about 4.5mg, or at least about 5mg.